Mazyar Ghanaat

New York Proton Center

Papers

1

Total Citations

3

H-Index

1

About

Mazyar Ghanaat is a urologic researcher whose work centers on prostate cancer, with a particular focus on the interplay between preoperative medications and disease presentation. His most cited study, published in the *Journal of Urology*, investigated the impact of statin use on prostate cancer biomarkers and pathology. The research demonstrated that men taking statins prior to radical prostatectomy had significantly lower preoperative PSA levels compared to non-users, yet showed no significant differences in adverse histopathologic outcomes such as Gleason score or tumor stage. This finding is clinically important because it suggests that statins may confound PSA screening without necessarily altering the underlying cancer aggressiveness, a nuance critical for both clinicians and patients. While Ghanaat’s citation count is modest, his contribution addresses a key question in prostate cancer management: whether common medications like statins can mask disease risk. His work, co-authored with prominent urologists including David Samadi, adds to the growing body of evidence on chemopreventive agents in urologic oncology, offering a cautionary note for interpreting PSA values in statin users.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
145 PREOPERATIVE STATIN USE ASSOCIATED WITH LOWER PSA BUT SIMILAR HISTOPATHOLOGIC OUTCOMES
3 citations · 2011
📈 Most Prolific Year: 2011 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: New York Proton Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago